Ann: ACTION3 IND Approved in China, page-36

Hi Vintage,

I think the lack of understanding comes from not reading what I posted above (role of DSMB in blinded clinical trials) and the difference of that to an Interim Analysis of blinded data. Not wasting anymore time as I said this morning, just ridiculous.

DXB have obviously been working hard on all new jurisdictions for the Ph3 ACTION trial in Asia, including China. It’s a significant announcement which we are all happy about & the inclusion of older Paediatric patients as well (approved by the FDA, Orphan Status) is nothing to be sneezed at. I don’t think that anyone here isn’t aware of the significance of the Interim Analysis in March 2024. If there were concerns of futility on unblinding of data from DSMB, the trial would have been halted already. That’s all I’m going to say now.